Company intelligence / Profile preview

diadexus

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

diadexus received FDA clearance for its PLAC ELISA Test and PLAC Test for Lp-PLA2 Activity to assess risk for coronary heart disease and ischemic stroke. Additional cardiac biomarkers in the pipeline focused on risk stratification and heart failure, but no therapeutic drugs developed. Company supported by extensive peer-reviewed validation.

Therapeutic areas: Cardiovascular
Modalities: Diagnostic testIn vitro diagnosticImmunoassay
Industry: Protein Biomarker Diagnostics

Partnerships

Pharmaceutical partners for biomarker incorporation in drug development

Beyond the preview

Go deeper on diadexus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on diadexus.

Explore the full profile